| Target Price | $15.10 |
| Price | $3.34 |
| Potential |
351.98%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Sonoma Pharmaceuticals, Inc. 2026 .
The average Sonoma Pharmaceuticals, Inc. target price is $15.10.
This is
351.98%
register free of charge
$15.54
365.27%
register free of charge
$14.95
347.54%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend Sonoma Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sonoma Pharmaceuticals, Inc. stock has an average upside potential 2026 of
351.98%
register free of charge
|
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 14.29 | 17.57 |
| 12.17% | 22.98% | |
| Net Margin | -24.21% | -12.60% |
| 36.27% | 47.96% |
3 Analysts have issued a sales forecast Sonoma Pharmaceuticals, Inc. 2026 . The average Sonoma Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
3 Sonoma Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average Sonoma Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.79 | -1.34 |
| 73.78% | 51.97% | |
| P/E | negative | |
| EV/Sales | 0.15 |
3 Analysts have issued a Sonoma Pharmaceuticals, Inc. forecast for earnings per share. The average Sonoma Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sonoma Pharmaceuticals, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


